The FURLONG study (NCT03787992) (7) showed that first-line treatment with furmonertinib in Chinese patients with advanced EGFR gene mutation NSCLC resulted in a median PFS of 20.8 months, which was 9.7 months longer than the 11.1 months in the gefitinib group. This evidence concerns the gene EGFR and non-small cell lung carcinoma.